A 74-year-old man, nonsmoker, presented with asthenia, inappetence, weight loss (about 10 kilograms in the last 6 months), right chest pain and some episodes of hemoptysis without fever.
DISCUSSION
Pyothorax-associated lymphoma (PAL) is a rare distinct variant of diffuse large B-cell lymphoma first described in 1987 by Aozasa et al. It mainly occurs in 60 -70 year-old Japanese people, and much more rarely in Caucasian patients, with marked male gender prevalence and a longstanding history (20 -67 years) of pyothorax or chronic pleuritis due to artificial pneumothorax for pleuro-pulmonary tuberculosis. 2 Patients clinically present with weight loss and chest pain, while imaging studies reveal pleural effusion and pleural thickening and/or masses. High level of serum NSE has been observed in some cases, then erroneously suggesting a small-cell carcinoma. 2 At morphology, PAL appears as a monotonous proliferation of medium-to-large sized nucleolated cells with amphophilic cytoplasm and immunoblastic/plasmablastic appearance. These cells show a very high labeling index by Ki-67/MIB-1 (80 -90%) and are positive for pan-B markers (CD20, CD79a, PAX-5) also variably co-expressing T-cell markers (CD2, CD3, CD7) and CD138, but not CD30 and ALK, then revealing a post/late germinal center B cell derivation. 3 PAL seems to be driven by EBV infection or less frequently by HHV-8. So, EBV may be likely detected by LMP-1 or EBNA2 expression or EBER probe by in-situ hybridization. 2, 4 Differential diagnosis on clinical and imaging grounds is quite broad. Primary pleural solid (mesothelioma, solitary fibrous tumors, synovial sarcoma, angiosarcoma) or metastatic tumors may mimic PAL. Correct diagnosis always require knowledge of the patient past medical history (tuberculous pleuritis treated by pneumothorax), a good biopsy (even obtained by transthoracic needle biopsy as first reported in our case) and appropriate ancillary studies (immunohistochemistry and molecular analysis). Once lymphoma is suspected, differential diagnosis should mainly posed in regards with primary effusion lymphoma (PEL). This latter, by contrast, occurs in patients with HIV infection clinically presenting with massive effusions of the body cavities without evidence of neoplastic masses. PEL cells are negative for B-cell and T-cell markers, whereas they express HHV-8 but not EBV in virtually all cases.
Although no well-established therapy exists and prognosis is very dismal (5-year survival accounts for 21.6% in the largest series), 5 PAL patients are generally treated by different combinations of chemotherapy and radiotherapy. Of note, local irradiation seems to control the disease. 2, 5 
